Efficacy and Safety of Sirolimus‐Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score‐Matched Study
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31402 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Cecilia Gobbi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Cardiac Catheters, Cardiovascular Agents, Coated Materials, Biocompatible. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Evidence regarding drug‐coated balloon (DCB)‐only angioplasty in de novo lesions of large vessels is still limited and mainly focused on paclitaxel‐coated balloon. We aimed to analyze the safety and efficacy of sirolimus‐coated balloon (SCB)‐only angioplasty in de novo lesions in large vessels compared to drug‐eluting stent (DES).
Methods
In this retrospective, dual‐center, case‐control study, we enrolled all consecutive patients treated between January 2022 and January 2024 with SCB‐only angioplasty in de novo lesion in large vessel (> 2.75 mm) compared to a propensity‐score matched contemporary population treated with DES. The primary endpoint was the rate of target lesion revascularization (TLR), while secondary endpoints were cardiac death (CD), target vessel revascularization (TVR), myocardial infarction (MI), and target lesion failure (TLF), defined as a composite of them.
Results
The mean age was 70.1 ± 9.8 years in the SCB group ( n = 92) and 67.9 ± 9.6 years in the DES group ( n = 92) ( p = 0.76). The median follow‐up was 19.5 ± 12 months in the SCB group and 20.1 ± 13.1 months in the DES group ( p = 0.47). TLR occurred in 6.7% of patients in the SCB group and 5.6% in the DES group ( p = 0.75). The incidence of MI, TVR, and TLF were similar between the two groups (4.3% vs 3.3%, p = 0.7, 2.2% vs 3.4%, p = 0.65% and 9.8% vs 8.7%, p = 0.79). CD occurred in 4.3% in the SCB group, compared to 3.3% in the DES group ( p = 0.70).
Conclusion
Our study suggests that SCB angioplasty is both safe and effective in the treatment of de novo lesions of large vessels compared with DES.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Department of Interventional Cardiology, Centro Cardiologico Monzino IRCCS, Milan, Italy.
ORCID-Profile: Francesco Giangiacomi
Zitieren
APA
Gobbi, C., Giangiacomi, F., Pasero, G., Faggiano, A., Barbieri, L., Tumminello, G., Colombo, F., Ruscica, M., Ardizzone, V., Genta, E., Mircoli, L., Galli, S., & Carugo, S. (2025). Efficacy and Safety of Sirolimus‐Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score‐Matched Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31402
Vancouver
Gobbi C, Giangiacomi F, Pasero G, Faggiano A, Barbieri L, Tumminello G, et al. Efficacy and Safety of Sirolimus‐Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score‐Matched Study. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31402
BibTeX
@article{Gobbi2025,
author = {Gobbi, Cecilia and Giangiacomi, Francesco and Pasero, Guido and Faggiano, Andrea and Barbieri, Lucia and Tumminello, Gabriele and Colombo, Federico and Ruscica, Massimiliano and Ardizzone, Valentina and Genta, Edoardo and Mircoli, Luca and Galli, Stefano and Carugo, Stefano},
title = {Efficacy and Safety of Sirolimus‐Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score‐Matched Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31402}
}
EUVIMED